Maturitas
Volume 56, Issue 2 , Pages 142-152 , 20 February 2007

Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells

Received 15 March 2006 ,Revised 30 June 2006 ,Accepted 5 July 2006.

References 

  1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–323
  2. Beral V Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–427
  3. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712
  4. Schatz RW, Soto AM, Sonnenschein C. Effects of interaction between estradiol-17β and progesterone on the proliferation of cloned breast tumor cells (MCF-7 and T47D). J Cell Physiol. 1985;124:386–390
  5. Poulin R, Baker D, Poirier D, Labrie F. Multiple actions of synthetic ’progestins’ on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Res Treat. 1991;17:197–210
  6. van der Burg B, Kalkhoven E, Isbrucker L, de Laat SW. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992;42:457–465
  7. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer. 1993;67:945–952
  8. Cappelletti V, Miodini P, Fioravanti L, Di Fronzo G. Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines. Anticancer Res. 1995;15:2551–2555
  9. Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. J Steroid Biochem Mol Biol. 1995;55:423–437
  10. Franke HR, Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas. 2003;46(Suppl. 1):S55–S58
  11. Seeger H, Wallwiener D, Mueck AO. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells. Horm Metab Res. 2003;35:76–80
  12. Miller WR. Aromatase activity in breast tissue. J Steroid Biochem Mol Biol. 1991;39:783–790
  13. James VH, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids. 1987;50:269–279
  14. Yue W, Wang JP, Hamilton CJ, Demers LM, Santen RJ. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 1998;58:927–932
  15. Pollow K, Boquoi E, Baumann J, Schmidt-Gollwitzer M, Pollow B. Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast tissue. Mol Cell Endocrinol. 1977;6:333–348
  16. Gunnarsson C, Olsson BM, Stal O Southeast Sweden Breast Cancer Group. Abnormal expression of 17β-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 2001;61:8448–8451
  17. Tseng L, Mazella J, Lee LY, Stone ML. Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma. J Steroid Biochem. 1983;19:1413–1417
  18. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol. 2000;72:23–27
  19. Suzuki T, Nakata T, Miki Y, et al. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. 2003;63:2762–2770
  20. Zhou DJ, Pompon D, Chen SA. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 1990;50:6949–6954
  21. Koshiba H, Kitawaki J, Teramoto M, et al. Expression of allograft inflammatory factor-1 in human eutopic endometrium and endometriosis: possible association with progression of endometriosis. J Clin Endocrinol Metab. 2005;90:529–537
  22. Kitawaki J, Koshiba H, Ishihara H, Kusuki I, Tsukamoto K, Honjo H. Progesterone induction of 17β-hydroxysteroid dehydrogenase type 2 during the secretory phase occurs in the endometrium of estrogen-dependent benign diseases but not in normal endometrium. J Clin Endocrinol Metab. 2000;85:3292–3296
  23. Bellino FL, Osawa Y. Localization of estrogen synthetase in the chorionic villus fraction after homogenization of human term placenta. J Clin Endocrinol Metab. 1977;44:699–707
  24. Kitawaki J, Fukuoka M, Yamamoto T, Honjo H, Okada H. Contribution of aromatase to the deoxyribonucleic acid synthesis of MCF-7 human breast cancer cells and its suppression by aromatase inhibitors. J Steroid Biochem Mol Biol. 1992;42:267–277
  25. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl. 1):S7–S16
  26. de Lignieres B, de Vathaire F, Fournier S, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric. 2002;5:332–340
  27. Coldham NG, James VH. A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17β-hydroxysteroid dehydrogenase activity. Int J Cancer. 1990;45:174–178
  28. Poutanen M, Moncharmont B, Vihko R. 17β-hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin. Cancer Res. 1992;52:290–294
  29. Pasqualini JR, Chetrite G, Nguyen BL, et al. Estrone sulfate-sulfatase and 17β-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol. 1995;53:407–412
  30. Pasqualini JR, Caubel P, Friedman AJ, Philippe JC, Chetrite GS. Norelgestromin as selective estrogen enzyme modulator in human breast cancer cell lines. Effect on sulfatase activity in comparison to medroxyprogesterone acetate. J Steroid Biochem Mol Biol. 2003;84:193–198
  31. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999;84:4559–4565
  32. Tjonneland A, Christensen J, Thomsen BL, et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer. 2004;100:2328–2337
  33. Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer. 2004;109:721–727

PII: S0378-5122(06)00272-6

doi: 10.1016/j.maturitas.2006.07.003

Maturitas
Volume 56, Issue 2 , Pages 142-152 , 20 February 2007

Article Tools

* Image Usage & Resolution